Paul Thompson is a professor and the director of Chemical Biology in the Department of Biochemistry and Molecular Pharmacology at UMass Medical School in Worcester, MA, where his research focuses on the development of novel therapeutics for a range of diseases including cancer, rheumatoid arthritis, inflammatory bowel disease and lupus. He is a world leader in the biology and biochemistry of the Protein arginine deiminases. Paul co-founded Padlock Therapeutics, which was recently acquired by Bristol-Myers Squibb. Paul received his BSc and PhD degrees from McMaster University in Canada before moving to the US to take a post-doctoral position with Philip Cole at the Johns Hopkins School of Medicine. Paul then moved to the University of South Carolina to begin his independent career before moving to the Department of Chemistry at The Scripps Research Institute, Scripps Florida, in May 2010. Paul subsequently moved to UMass in August 2014. Paul has published more than 95 articles in major scientific journals including Nature, Cell, Nature Structural & Molecular Biology and the Journal of the American Chemical Society. Paul has also won a number of awards, including a Canadian Institutes of Health Research Postdoctoral Fellowship and a Camille Dreyfus Teacher-Scholar Award.